Women’s Health
The FDA has approved a hormone-free, copper intrauterine device (IUD; Miudella; Sebela Pharmaceuticals) for the prevention of pregnancy in people of reproductive potential for up to 3 years, making it the first hormone-free IUD to be FDA approved in more than 40 years, according to a press release. Read More ›
Expectant and new mothers who have TRICARE both in the United States, and now abroad, have more options thanks to an expansion of the program’s Childbirth and Breastfeeding Support Demonstration (CBSD) arm. Read More ›
Fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) has been approved by FDA officials for use in patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, who have progressed on one or more endocrine therapies in the metastatic setting. Read More ›
An Executive Order signed in March 2024 put a strong emphasis on the role of evaluating and meeting the health needs of female service members and veterans. Read More ›
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib. Read More ›
Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer. Read More ›